A First in Human, Randomized, Double-Blind Study to Assess Safety and Tolerability, Pharmacokinetic and Pharmacodynamic Effects of HTD4010 in Healthy Participants
Phase of Trial: Phase I
Latest Information Update: 09 Jun 2016
At a glance
- Drugs HTD 4010 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; First in man
- Sponsors HighTide Biopharma
- 06 Jun 2016 Treatment arms changed from 8 to 4; with removal of multiple ascending doses and type 2 diabetic patients.
- 06 Jun 2016 Status changed from recruiting to completed.
- 19 Oct 2015 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.